- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03993938
Pleth Variability Index (PVI) as a Measure of Volume Status During Transcatheter Mitral Valve Repair
May 30, 2022 updated by: Ashwin Vaidyanathan, MD, Henry Ford Health System
Transcatheter mitral valve repair in the form of MitraClip® is a safe and effective alternative to surgical mitral valve repair/replacement in patients with high operative morbidity and mortality risk.
Successful MitraClip application depends on intraprocedural quantification of mitral regurgitation and left atrial pressure (LAP) monitoring.
The pleth variability index (PVI) is a noninvasive, dynamic index based on analysis of the respiratory variations in the plethysmographic waveform recorded transcutaneously by the pulse oximeter.
Studies demonstrate that PVI is accurate in predicting fluid responsiveness in mechanically ventilated adult patients.
In this study, we wish to measure PVI during TMVR and correlate with invasive indices such as left atrial pressure (LAP) and stroke volume variation.
Our study hopes to provide a real-time non-invasive alternative to invasive indices to better guide fluid management and improve hemodynamics.
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients with mitral regurgitation undergoing transcatheter mitral valve repair(TMVR) with Mitra-Clip(R) at Henry Ford Hospital - Main Campus.
Exclusion Criteria:
- MitraClip(R) procedure unsuccessful (defined as no clip deployment and/or procedural interruption due to complication), concomitant aortic regurgitation or stenosis of moderate or greater degree existed, patients with grade II or above diastolic dysfunction on echocardiography, previous mitral valve intervention (either surgical or percutaneous), patients requiring continuous vasopressor infusions during the procedure, or patients in whom PVI monitoring was not performed due to technical issues, patients with atrial fibrillation, or preprocedure moderate or greater mitral stenosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Patients for TMVR
Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
|
Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure.
After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes.
Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment.
Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delta PVI to Delta LAP Correlation During MitraClip Placement
Time Frame: Intraprocedure
|
Delta pleth variability index (PVI) and delta left atrial pressure (LAP) are calculated by subtracting the values of LAP (as obtained intraprocedurally) and corresponding PVI value (as recorded by the Masimo Radical-7 probe) from the LAP and PVI value respectively after MitraClip placement.
The delta PVI and delta LAP for the sample patient population are correlated to obtain the Pearson correlation coefficient and p-value
|
Intraprocedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2019
Primary Completion (ACTUAL)
June 1, 2021
Study Completion (ACTUAL)
June 1, 2021
Study Registration Dates
First Submitted
February 17, 2019
First Submitted That Met QC Criteria
June 19, 2019
First Posted (ACTUAL)
June 21, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 24, 2022
Last Update Submitted That Met QC Criteria
May 30, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1 (Other Identifier: Mobile Health and Wellness Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Xiao-dong ZhuangNot yet recruitingMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationChina
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve RegurgitationUnited States
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Sun Yat-sen UniversityRecruitingMitral Insufficiency | Mitral Regurgitation (MR)China
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
Clinical Trials on PVI measurement
-
Abbott Medical DevicesCompletedAtrial FibrillationCanada, Australia
-
Charles University, Czech RepublicUniversity Hospital Olomouc; Faculty Hospital Kralovske Vinohrady; University... and other collaboratorsNot yet recruiting
-
Meshalkin Research Institute of Pathology of CirculationUnknownAtrial Fibrillation | Arterial HypertensionRussian Federation, United States
-
AtriCure, Inc.Completed
-
VZW Cardiovascular Research Center AalstBiosense Webster, Inc.RecruitingAtrial Fibrillation (AF) | Paroxysmal AFBelgium
-
Wake Forest University Health SciencesTerminatedAtrial FibrillationUnited States
-
The Second Affiliated Hospital of Kunming Medical...First Affiliated Hospital of Kunming Medical UniversityActive, not recruitingAtrial FibrillationChina
-
Osaka Cardiovascular ConferenceUnknownRecurrence | Atrial Fibrillation | Catheter Ablation
-
Volta MedicalCardiaBase; FortreaCompletedAtrial FibrillationUnited States, Germany, Belgium, France, Netherlands
-
The Second Affiliated Hospital of Kunming Medical...Completed